Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study

Kód výsledku v IS VaVaI

RIV/00216208:11110/15:10296532 - isvavai.cz

Nalezeny alternativní kódy

RIV/68407700:21230/15:00230709 RIV/00064165:_____/15:10296532

Výsledek na webu

http://dx.doi.org/10.1007/s00702-015-1363-y

DOI - Digital Object Identifier

10.1007/s00702-015-1363-y

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study

Popis výsledku v původním jazyce

Although speech dysfluencies have been hypothesized to be associated with abnormal function of dopaminergic system, the effects of dopaminergic medication on speech fluency in Parkinson's disease (PD) have not been systematically studied. The aim of thepresent study was, therefore, to investigate the long-term effect of dopaminergic medication on speech fluency in PD. Fourteen de novo PD patients with no history of developmental stuttering and 14 age- and sex-matched healthy controls (HC) were recruited. PD subjects were examined three times; before the initiation of dopaminergic treatment and twice in following 6 years. The percentage of dysfluent words was calculated from reading passage and monolog. The amount of medication was expressed by cumulative doses of l-dopa equivalent. After 3-6 years of dopaminergic therapy, PD patients exhibited significantly more dysfluent events compared to healthy subjects as well as to their own speech performance before the introduction of dopamine

Název v anglickém jazyce

Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study

Popis výsledku anglicky

Although speech dysfluencies have been hypothesized to be associated with abnormal function of dopaminergic system, the effects of dopaminergic medication on speech fluency in Parkinson's disease (PD) have not been systematically studied. The aim of thepresent study was, therefore, to investigate the long-term effect of dopaminergic medication on speech fluency in PD. Fourteen de novo PD patients with no history of developmental stuttering and 14 age- and sex-matched healthy controls (HC) were recruited. PD subjects were examined three times; before the initiation of dopaminergic treatment and twice in following 6 years. The percentage of dysfluent words was calculated from reading passage and monolog. The amount of medication was expressed by cumulative doses of l-dopa equivalent. After 3-6 years of dopaminergic therapy, PD patients exhibited significantly more dysfluent events compared to healthy subjects as well as to their own speech performance before the introduction of dopamine

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

GAP102/12/2230: Analýza hlasu a řeči pacientů s onemocněními centrální nervové soustavy

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Svazek periodika

122

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

8

Strana od-do

1135-1142

Kód UT WoS článku

000358387200007

EID výsledku v databázi Scopus

2-s2.0-84938826826